These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 1913660)
21. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma. Kleymenova EV; Bianchi AA; Kley N; Pylev LN; Walker CL Mol Carcinog; 1997 Jan; 18(1):54-60. PubMed ID: 9022813 [TBL] [Abstract][Full Text] [Related]
22. Mutations in the p53 gene in primary human breast cancers. Osborne RJ; Merlo GR; Mitsudomi T; Venesio T; Liscia DS; Cappa AP; Chiba I; Takahashi T; Nau MM; Callahan R Cancer Res; 1991 Nov; 51(22):6194-8. PubMed ID: 1682043 [TBL] [Abstract][Full Text] [Related]
23. Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids. Isfort RJ; Cody DB; Lovell GJ; Gioeli D; Weissman BE; Doersen CJ Mol Carcinog; 1999 May; 25(1):30-41. PubMed ID: 10331742 [TBL] [Abstract][Full Text] [Related]
24. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Shigemitsu K; Sekido Y; Usami N; Mori S; Sato M; Horio Y; Hasegawa Y; Bader SA; Gazdar AF; Minna JD; Hida T; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Shimokata K Oncogene; 2001 Jul; 20(31):4249-57. PubMed ID: 11464291 [TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. Heidenreich A; Gaddipati JP; Moul JW; Srivastava S J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401 [TBL] [Abstract][Full Text] [Related]
26. Mutations of the p53 gene are not detectable in human testicular tumors. Fleischhacker M; Strohmeyer T; Imai Y; Slamon DJ; Koeffler HP Mod Pathol; 1994 May; 7(4):435-9. PubMed ID: 8066072 [TBL] [Abstract][Full Text] [Related]
27. Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: possible role in biological and clinical behavior of tumors. Gerdes H; Chen Q; Elahi AH; Sircar A; Goldberg E; Winawer D; Urmacher C; Winawer SJ; Jhanwar SC Anticancer Res; 1995; 15(1):13-24. PubMed ID: 7733622 [TBL] [Abstract][Full Text] [Related]
28. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786 [TBL] [Abstract][Full Text] [Related]
29. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Van Leeuwen IS; Hellmèn E; Cornelisse CJ; Van den Burgh B; Rutteman GR Anticancer Res; 1996; 16(6B):3737-44. PubMed ID: 9042250 [TBL] [Abstract][Full Text] [Related]
30. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572 [TBL] [Abstract][Full Text] [Related]
31. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity and p53 gene mutations in breast cancer. Deng G; Chen LC; Schott DR; Thor A; Bhargava V; Ljung BM; Chew K; Smith HS Cancer Res; 1994 Jan; 54(2):499-505. PubMed ID: 8275488 [TBL] [Abstract][Full Text] [Related]
33. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Wagata T; Shibagaki I; Imamura M; Shimada Y; Toguchida J; Yandell DW; Ikenaga M; Tobe T; Ishizaki K Cancer Res; 1993 Feb; 53(4):846-50. PubMed ID: 8094033 [TBL] [Abstract][Full Text] [Related]
34. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Badiali M; Iolascon A; Loda M; Scheithauer BW; Basso G; Trentini GP; Giangaspero F Diagn Mol Pathol; 1993 Mar; 2(1):23-8. PubMed ID: 8287222 [TBL] [Abstract][Full Text] [Related]
35. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations. Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422 [TBL] [Abstract][Full Text] [Related]
36. Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Futreal PA; Cochran C; Marks JR; Iglehart JD; Zimmerman W; Barrett JC; Wiseman RW Cancer Res; 1994 Apr; 54(7):1791-4. PubMed ID: 7511052 [TBL] [Abstract][Full Text] [Related]
37. Mutations in the p53 gene in myelodysplastic syndromes. Jonveaux P; Fenaux P; Quiquandon I; Pignon JM; Laï JL; Loucheux-Lefebvre MH; Goossens M; Bauters F; Berger R Oncogene; 1991 Dec; 6(12):2243-7. PubMed ID: 1766671 [TBL] [Abstract][Full Text] [Related]
38. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas. Jin W; Xu X; Yang T; Hua Z Chin Med J (Engl); 2000 Jul; 113(7):662-6. PubMed ID: 11776043 [TBL] [Abstract][Full Text] [Related]
39. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Stratton MR; Moss S; Warren W; Patterson H; Clark J; Fisher C; Fletcher CD; Ball A; Thomas M; Gusterson BA Oncogene; 1990 Sep; 5(9):1297-301. PubMed ID: 2216456 [TBL] [Abstract][Full Text] [Related]
40. Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines. Hosono S; Lee CS; Chou MJ; Yang CS; Shih CH Oncogene; 1991 Feb; 6(2):237-43. PubMed ID: 1847999 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]